Il ruolo dell’immunoterapia adiuvante nei pazienti con melanoma BRAF-mutato

Translated title of the contribution: The role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma

Francesco Spagnolo

Research output: Contribution to journalReview articlepeer-review

Abstract

The introduction of anti-PD-1 drugs as an adjuvant treatment for high risk melanoma has radically changed the everyday clinical practice, with an impact on the reduction of the risk of relapse close to 50%, as observed in phase 3 clinical trials. In patients whose tumors harbor a BRAF mutation, the combination of BRAF plus MEK inhibitors is also a valuable option, with outcomes in terms of 3-year RFS similar to those observed with anti-PD-1 immunotherapy. However, numerous questions remain unanswered, particularly which is the best treatment in BRAF-mutant patients. The aim of this review was to analyze the results of randomized phase 3 clinical trials, with a focus on some hot topics and discussing the role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma.

Translated title of the contributionThe role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma
Original languageItalian
Pages (from-to)E39-E47
JournalRecenti Progressi in Medicina
Volume111
Issue number12
DOIs
Publication statusPublished - Dec 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The role of immunotherapy for the adjuvant treatment of BRAF-mutant melanoma'. Together they form a unique fingerprint.

Cite this